CD
SVA

Christopher Davis’s Sinovac Biotech, Ltd SVA Stock Holding History

Christopher Davis’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,250,546
Closed -$7.05M – 199
2014
Q2 		$7.05M Buy
1,250,546
+6,340
+0.5% +$38.5K 0.02% 146
2014
Q1 		$8.96M Buy
1,244,206
+65,600
+6% +$434K 0.02% 126
2013
Q4 		$7.21M Sell
1,178,606
-294,737
-20% -$1.78M 0.02% 140
2013
Q3 		$8.81M Sell
1,473,343
-1,153,888
-44% -$5.52M 0.02% 128
2013
Q2 		$10.3M Buy
+2,627,231
New +$9.78M 0.03% 133

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Christopher Davis's SVA Position: Q3 2014 in Review

Christopher Davis sold out of Sinovac Biotech, Ltd (SVA) in Q3 2014, closing a stake of 1,250,546 shares — an estimated $7.05M sold.

Christopher Davis first reported a position in SVA in Q2 2013 and held it in 5 quarters. The position peaked at $10.3M in Q2 2013. 45 funds tracked by Wall St. Rank hold SVA as of Q3 2014.

  • Christopher Davis reported no remaining Sinovac Biotech, Ltd position as of Q3 2014 after selling out during the quarter.
  • Christopher Davis sold 1,250,546 Sinovac Biotech, Ltd shares in Q3 2014, an estimated $7.05M.
  • Christopher Davis first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 5 quarters.
  • Christopher Davis's Sinovac Biotech, Ltd position peaked at $10.3M in Q2 2013.
  • 45 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2014.

Based on Davis Selected Advisers's 13F filing for Q3 2014, filed 12 Nov 2014.